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In a previous study, a mammalian orthoreovirus mutant was isolated based on its 
increased ability to infect interferon-defective Vero cells and was referred to as Vero-cells-
adapted virus (VeroAV). This virus exhibits reduced ability to resist the antiviral effect of 
interferon. In the present study, the complete genome sequence of VeroAV was first determined. 
Reverse genetics was then used to identify a unique mutation on the S1 gene, overlapping the σ1 
and σ1s reading frame, resulting in increased sensitivity to interferon. A virus lacking σ1s 
expression consecutive to mutation of its initiation codon was then shown to exhibit a further 
increase in sensitivity to interferon, supporting the idea that σ1s is the viral protein responsible. 
This identification of a new determinant of reovirus sensitivity to interferon gives credentials to 
the idea that multiple reovirus genes are responsible for the level of interferon induction and 
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Highlights: 
•A Vero-cell-adapted reovirus exhibits increased sensitivity to interferon. 
•Sensitivity was assigned to a mutation in the S1 gene altering both σ1 and σ1s proteins. 
•Abolishing σ1s protein expression further increase sensitivity to interferon. 
•This reveals a new function for the small σ1s protein. 
•This stresses the multigenic nature of the reovirus determinants of interferon control.
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Introduction 
In the last few years, it has been shown that multiple virus genes are often involved in the 
control of the innate immune response mediated by the interferon signaling network (Fensterl et 
al., 2015; Beachboard and Horner, 2016; Schulz and Mossman, 2016; Garcia-Sastre, 2017). 
Different viruses were also shown to exhibit many sequence changes when grown under 
conditions where the selective pressure to keep viral moderators of the interferon response is 
removed (Perez-Cidoncha et al., 2014; Hernández-Alonso et al., 2015; Garijo et al., 2016; 
Weber-Gerlach et al., 2016; Du et al., 2018). 
The interferon response is well known to be of critical importance as a determinant of 
viral pathogenicity and a better understanding of viral determinants involved is thus fundamental 
for epidemiological surveillance as well as choosing the appropriate treatment option. It is also 
well accepted that the interferon response often plays a role in determining the ability of a virus 
to discriminate between parental and transformed/cancer cells; the latter frequently, but not 
always, exhibiting a reduced interferon response (Randall and Goodburn, 2008; Naik and 
Russell, 2009; Katsoulidis et al., 2010; Kaufman et al., 2015; Ebrahimi et al., 2017; 
Matveeva and Chumakov, 2018). Since a plethora of viruses are presently considered as 
possible oncolytic viruses for cancer treatment (Ilkow et al., 2014; Miest and Cattaneo, 2014; 
Pikor et al., 2015; Turnbull et al., 2015), this aspect could be of importance. A better 
understanding could lead to the selection of better optimized and appropriate virus strains for 
given cancer cell types (Pikor et al., 2015; Sanjuán and Grdzelishvili, 2015). 
Mammalian orthoreovirus (herein referred to as reovirus) is among the viruses presently 
under study for their possible use as anticancer agents; it presents the advantage of exhibiting a 
natural tropism for cancer cells (Black and Morris, 2012; Maitra et al., 2012; Clements et al., 
2014; Chakrabarty et al., 2015). The interferon response does appear to be at least partly 
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involved in the oncoselectivity of reovirus (Strong et al., 1998; Rudd and Lemay, 2005; 
Shmulevitz et al., 2010). Another advantage of reovirus as a putative agent in virotherapy is that 
it is believed to be essentially nonpathogenic in humans. However, this does not preclude the 
possible emergence of novel viral strains of increased pathogenicity, as suggested in the last few 
years (Kohl and Kurth, 2015; Thimmasandra Narayanappa et al., 2015; Yang et al., 2015). 
The importance of the interferon response in viral pathogenicity does not need to be further 
stressed. This is also the case in reovirus whose pathogenicity in the heart and brain of animal 
models is clearly linked to its ability to control, or not, the interferon response (Sherry et al., 
1998; Goody et al., 2007; Zurney et al., 2007; Tyler et al., 2010; Dionne et al., 2011; Irvin et 
al., 2012; Wu et al., 2018). Also, a recent study has raised the possibility that the virus 
contributes to the development of celiac disease in humans and, once again, there is a likely 
possibility that the interferon-mediated immune response is involved (Bouziat et al., 2017). 
It thus appears to be essential to gain a further understanding of the viral determinants that 
control induction of the interferon response and the sensitivity of different viral isolates to this 
response. This is one of many approaches that could lead to next-generation reovirus variants that 
will be either more potent or more specific in their oncolytic effect (Mohamed et al., 2015; 
Kemp et al., 2016). In this context, a reovirus mutant was previously obtained by the 
establishment of persistence and thus long-term growth of the virus in Vero cells (Jabre et al., 
2013; Sandekian and Lemay, 2015b). These cells are known to be deficient in production of 
interferon, interferon regulatory factor 3 (IRF3) and interferon-induced protein kinase PKR 
(Desmyter et al., 1968; Emeny and Morgan, 1979; Park et al., 2006; Chew et al., 2009). As 
somewhat expected, the resulting Vero-cell-adapted virus (VeroAV) was both adapted for better 
growth in Vero cells and exhibited an increased sensitivity to interferon compared to the original 
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wild-type virus (Jabre et al., 2013; Sandekian and Lemay, 2015b); however, this last aspect 
was not examined in detail. 
In the present study, the complete genome sequence of VeroAV was first determined and 
revealed actual amino acids substitutions in four virus genes. The plasmid-based reverse genetics 
(Kobayashi et al., 2007, 2010) was then applied to introduce each of these mutant genes in the 
original wild-type interferon-resistant genetic background. This allowed to confirm a strongly 
increased interferon sensitivity with no difference in interferon secretion and the phenotype was 
assigned to the S1 gene that harbors two separate mutations. The mutation responsible for 
increased interferon sensitivity was then shown to be located in the region of the S1 gene 
corresponding to the amino-proximal region of σ1 where its reading frame overlap with that of 
σ1s. Introduction of a stop codon in the σ1s-encoding reading frame of an otherwise wild-type 
virus also increases interferon sensitivity indicating that σ1s is the most likely determinant 
involved in the virus mutant. The σ1s protein thus needs to be added to the many reovirus 




Sequencing of the VeroAV genome 
 To determine the differences in sequence between the Vero-cell-adapted virus (Jabre et 
al., 2013; Sandekian and Lemay, 2015b) and the original serotype 3 Dearing 
(T3/Human/Ohio/Dearing/55) laboratory strain (T3DS), the whole coding sequence of the 
genome was obtained. Reverse transcription-PCR on the semi-purified viral genome from both 
the mutant and wild-type laboratory stocks was used to generate PCR products that were directly 
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subjected to sequencing, as described in Materials and Methods and previously used in the 
laboratory. In a previous study, the sequence of S1 and M2 was solely reported (Sandekian et 
al., 2015b). 
Overall, four genes were found to exhibit nonsynonymous mutations compared to the 
wild-type resulting in a total of 7 amino acids substitutions on 5 proteins since one of the two 
mutations overlaps the two reading frames in S1 (Table 1). Only three additional silent 
nucleotide substitutions were found between the wild-type and VeroAV (data not shown). All 
sequences were deposited in GenBank: the wild-type T3DS sequences were previously deposited 
under accession numbers KP208804 to KP208813 and sequences for VeroAV were added in the 
present study under accession numbers MK238541, MK238542 and MK246415 to MK246422. 
 
Reverse genetics rescue and characterization of VeroAV 
To confirm that the amino acid substitutions in the four VeroAV genes (S1, M1, M2 and 
M3) are actually responsible for the difference in interferon sensitivity between the two viruses, 
they were introduced in the T3DS background made of the other 6 genes. Cells were infected with 
the resulting virus and supernatants recovered to measure secreted β and α-interferons, as 
described in Materials and methods. 
The rescued VeroAV induced similarly low amount of interferon as the control rescued 
wild-type, T3DS (Fig.1). This is consistent with previous observations using a less direct 
approach where the ability of infected cells supernatants from the original T3DS and VeroAV 
were shown to exhibit a similar ability to protect against another virus (Jabre et al., 2013).  
Interferon sensitivity was then examined first by the decrease of the virus titer in the 
presence of a near-saturating (200 international units [IU] per ml) concentration of type I 
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interferon (mouse ß-interferon without carrier protein, PBL Assay Science). As previously shown 
(Sandekian and Lemay, 2015a; Lanoie and Lemay, 2018), the rescued T3DS was quite 
resistant under these conditions. In contrast, the rescued VeroAV was essentially a hundredfold 
more sensitive (Fig. 2), as previously observed with the original VeroAV (Jabre et al., 2013). 
Secondly, the sensitivity to different concentrations of interferon was determined as described in 
Materials and methods and as used before (Sandekian and Lemay, 2015a; Lanoie and Lemay, 
2018). Briefly, consecutive twofold dilutions of interferon were prepared from 250 IU/ml to 
approximately 4 IU/ml in single wells of a microplate; cell lysis in each well (4-5 days post-
infection at a MOI of 0.05) was measured by transparency following methylene blue-staining 
compared with control well containing mock-infected cells. Again, the rescued VeroAV was 
significantly more sensitive than the wild-type T3DS (Fig. 3); using this approach, the 
concentration of interferon needed to decrease cell lysis from 100% (in the absence of interferon) 
to 50% was more than 250 IU/ml for T3DS but less than 2.5 IU/ml for VeroAV. 
 
Introduction of different VeroAV genes in the T3DS background 
Having confirmed that the four genes are actually sufficient to increase sensitivity to 
interferon, the three genes M1, M2 and M3 of VeroAV were then separately introduced in the 
wild-type T3DS background from which VeroAV was originally derived. In addition, a 
combination of both M2 and S1 of VeroAV was also introduced in the same background. This 
was necessary to examine the effect of S1 since it was previously shown that this mutant gene is 
poorly compatible with the wild-type M2 gene thus rendering analysis impossible due to 
strikingly reduced viral titer and virus replication (Sandekian and Lemay, 2015b).  
The introduction of either the M1, M2 or M3 gene by themselves had no effect on the 
interferon sensitivity using either the reduction of titer assay or the interferon dilution assay (Fig. 
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2 and Fig.3 upper panel). In contrast the introduction of S1 (with M2) resulted in a virus as 
sensitive as VeroAV (Fig. 2 and Fig.3 upper panel), indicating that the S1 gene is the only 
determinant of this sensitivity. 
 
Introduction of single mutations in the S1 gene 
Having established that the S1 gene is responsible for the increased interferon sensitivity 
of VeroAV, each of the two mutations on this gene (resulting in Q78P and N198K amino acids 
substitutions in σ1) were solely introduced. When interferon sensitivity was assessed, the Q78P 
substitution was found to be both necessary and sufficient to fully reconstitute the interferon 
sensitivity of VeroAV (Fig. 2 and Fig.3 lower panel). 
The involvement in interferon sensitivity of the virion binding region of the viral 
attachment protein appears unlikely. However, the mutation resulting in Q78P substitution on σ1 
also overlaps the reading frame for the small nonstructural σ1s in S1, the Q78P substitution in σ1 
thus also results in a N59H substitution in σ1s. 
 
Effect of σ1s on interferon sensitivity 
The previous data indicate that the amino acid substitution in the small σ1s protein is 
most likely responsible for increased interferon sensitivity of VeroAV, and suggest the 
importance of σ1s in interferon control. In order to further support this idea, the initiation codon 
for the σ1s protein was mutated from ATG to ACG on the plasmid in order to prevent its 
synthesis. This was done without affecting the σ1-encoding sequence, thus generating a virus 
harboring σ1 from the wild-type T3DS in the absence of any σ1s expression, as described by 
others, (Boehme et al., 2009). Although σ1s was shown to be nonessential to viral replication per 
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se (Rodgers et al., 1998), other data indicate that it plays important roles in cell-cycle arrest and 
apoptosis consecutive to viral infection (Poggioli et al., 2000, 2001; Boehme et al., 2013). 
Recently, an additional role in the efficient synthesis of viral proteins was also observed, at least 
with some viral strains and cell types (Phillips et al., 2018). In the present study, the T3DS virus 
lacking σ1s (T3DS-σ1s-K/O) was examined for its ability to kill and lyse L929 cells at different 
multiplicity of infection, as described in previous studies (Lanoie and Lemay, 2018). This 
revealed a significant decrease in the cytopathic effects of σ1s-K/O virus, especially at low 
multiplicity of infection (data not shown). This indicates that the σ1s protein does have a more 
important role in viral replication, and/or effect on the host cell, than initially suspected. This 
rendered difficult the analysis of interferon sensitivity by the interferon dilution method but the 
diminution of viral titer could still be used and revealed that this virus is actually a further 
hundredfold more sensitive to interferon than the virus mutant (Fig. 4). This was also observed 
either in the presence or absence of the M2 gene of VeroAV, confirming the sole role of the 
mutation corresponding to Q78P of σ1 (N59H in σ1s) of VeroAV S1 in interferon sensitivity of 
the virus mutant and the important role of σ1s as an anti-interferon determinant. 
 
Discussion 
Efforts are currently underway to further understand reovirus determinants of 
pathogenesis and oncolytic activity and the interferon response is clearly central in these 
properties of various strains or isolates. Such efforts should possibly lead to the development of 
better adapted viruses for anticancer virotherapy applications (Mohamed et al., 2015; Kemp et 
al., 2016). In previous works, viruses were selected in the laboratory using combinations of 
chemical mutagenesis, high-passage virus stocks and selection of new viruses. The use of viral 
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persistence in cells exhibiting giving properties could be an interesting approach to select new, 
more selective, viruses for virotherapy applications (Kim et al., 2010). 
Using this viral persistence strategy, the Vero-cell-adapted virus (VeroAV) was 
previously obtained in the laboratory. This virus exhibits an adaptation at a level of increased 
binding to sialic acid while also showing increased sensitivity to interferon (Jabre et al., 2013; 
Sandekian and Lemay, 2015b). This is in accordance with the fact that Vero cells are defective 
in interferon response. Interestingly, selection of a virus mutant with increased affinity for sialic 
acid in murine erythroleukemia cells (tryptophan to basic arginine substitution at position 202) as 
in the case of VeroAV in Vero cells (asparagine to basic lysine substitution at position 198) 
previously led to the identification of a σ1s knockout virus (Rodgers et al., 1998). It is tempting 
to speculate that the gain in infectivity due to increased sialic acid binding somehow compensates 
for the loss of σ1s in these viruses. Accordingly, the sole introduction of the N59H amino acid 
substitution and especially the introduction of a stop codon in the σ1s reading frame, was 
observed to reduce host-cell lysis in the present study. Further work will be needed to determine 
the impact of σ1s in different viral genetic backgrounds and different cell types. 
Induction of and sensitivity to interferon are two interrelated phenomena, as previously 
shown for example during reovirus infection (Sherry et al., 1998) but they can also be viewed as 
somewhat independent from each other in some cases. Previous work in the laboratory has shown 
that a virus selected for increased sensitivity to interferon (Rudd et al., 2005) does not induce 
increased interferon secretion (Sandekian and Lemay, 2015a). Similarly, this virus does not 
exhibit apparent differences in the observed changes of cellular gene expression during infection 
compared to the parental wild-type virus (Boudreault et al., 2016 and unpublished data). More 
recently, comparisons were also made between T3DS, the virus laboratory stock, and T3DK, the 
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virus recovered from the original reverse genetics plasmids (Kobayashi et al., 2007). Increased 
interferon secretion was attributed to both the µ2 and λ1 protein while increased sensitivity is 
also partly dependent of µ2 with λ2 also involved (Lanoie and Lemay, 2018). 
In previous works, the VeroAV genome was only partly sequenced and it was established 
that both the µ1 and σ1 proteins are altered (Jabre et al., 2013; Sandekian et al., 2015b). Since 
µ1 was altered in a way that affects viral disassembly, it was hypothesized that this could also 
affect its interaction with its binding partner σ3 (Jabre et al., 2013). This protein has long been 
considered to be important in the control of the interferon-induced protein kinase PKR (Jacobs 
and Langland, 1998; Samuel, 1998; Schiff, 2008; Sherry, 2009; Schiff). Although, at the time, 
this appeared as a logical explanation to explain increased interferon sensitivity exhibited by 
VeroAV, it turned out not to be the case. 
This involvement of σ1s in the interferon sensitivity phenotype was somewhat surprising. 
The protein was recently shown to be involved in the efficiency of protein synthesis, although not 
in the same cell type and not the same virus strain (Phillips et al., 2018). It is also known that the 
protein has at least a partial nuclear localization (Rodgers et al., 1998; Hoyt et al., 2004; 
Boehme et al., 2011, 2013), suggesting that it may affect the expression of certain genes. 
Alternatively, the protein might interact with a factor important for the interferon response, 
beyond induction of interferon per se, as shown for the µ2-IRF9 or µNS-IRF3 interactions 
(Zurney et al., 2009; Stanifer et al., 2017). The mutant σ1s is still expressed but was found at a 
reduced level compared to the wild-type by immunoblotting (data not shown). Considering that 
the interferon sensitivity is at least a hundredfold higher when σ1s is completely absent, even a 
small reduction in the level of the protein could well be enough to explain the phenotype; 
however, an additional loss of function cannot be excluded at this point. Clearly the availability 
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of a virus mutant with an intermediate phenotype could facilitate further study of σ1s impact on 
the interferon response and related effect on viral pathogenesis. Interestingly, approximately 50% 
of the 120 amino acids of σ1s, including asparagine 59, are conserved in 98% or more of the 55 
type 3 viral sequences recovered from the NCBI database (data not shown). In contrast,very 
limited sequence conservations was found between serotypes 1, 2 and 3 (data not shown). It will 
thus be of interest to compare the effect, if any, of σ1s in other viral serotypes and to identify the 
common structure involved. 
The σ1s protein is well known for its importance in viral propagation in vivo (Boehme et 
al., 2009, 2011; Nygaard et al., 2013). It is tempting to speculate that this is due to its role in the 
control of the interferon response and it will be of interest to pursue these studies. The 
availability of viruses differing specifically in one viral determinant of interferon induction or 
sensitivity should certainly contribute to a better understanding of the importance of interferon in 
viral pathogenesis. 
The σ1s protein should thus be added to σ3, µ2, µNS, λ1 and λ2, as proteins probably 
involved in either the induction of or sensitivity to the interferon response (Sherry et al., 1998; 
Sherry 2009; Sherry et al., 2009; Zurney et al., 2009; Irvin et al., 2012; Stebbing et al., 2014; 
Sandekian and Lemay 2015a; Stanifer et al., 2017; Lanoie and Lemay, 2018). 
It thus appears that reovirus is one further example of virus coevolution with the innate 
immune response leading, as previously mentioned, to a loss of the ability of the virus to resist 
interferon when this selective pressure is removed (Perez-Cidoncha et al., 2014; Hernández-
Alonso et al., 2015; Garijo et al., 2016; Weber-Gerlach et al., 2016; Du et al., 2018). 
Interestingly, rotavirus, another dsRNA virus of the Reoviridae family, also uses at least three of 
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its proteins in the control of the interferon response (Sherry 2009; Sherry et al., 2009; Arnold 
et al., 2013; López et al., 2015). 
This also raises the possibility of combining these determinants in order to further 
modulate the interferon response. This could lead to further applications of the virus not only as 
an oncolytic agent but also as a gene or vaccine vector, as proposed previously by various authors 
(Roner and Joklik, 2001; Rouault and Lemay, 2003; Kobayashi et al., 2007; Brochu-
Lafontaine and Lemay, 2012; Demidenko et al., 2013; Mohamed et al., 2015; van den 
Wollenberg et al., 2015; Boehme et al., 2016; Kemp et al., 2016; Eaton et al., 2017; Stuart et 
al., 2017). 
 
Materials and methods 
 
Cell lines and viruses 
L929 mouse fibroblasts and Vero cells were originally obtained from the American type 
culture collection (ATCC®). The baby hamster kidney cell line (BHK) stably expressing the T7 
RNA polymerase has been described was a generous gift from the laboratory of Dr. John Hiscott 
(Lady Davis Research Institute, Montréal, Canada). All cell lines were grown in minimal Eagle 
medium (MEM) with 5% fetal bovine serum. 
Wild-type laboratory stock of reovirus type 3 (T3DS) was previously described (Lanoie 
and Lemay 2018; Sandekian and Lemay 2015a,b) and recovered by introduction of the 
appropriate mutations in the plasmids encoding the wild-type virus from Dr. Terry Dermody’s 
laboratory (T3DK). The Vero-cell-adapted virus (VeroAV) was also previously described (Jabre 
et al. 2013; Sandekian and Lemay 2015b). Viruses harboring various combinations of genes 
from T3DS and VeroAV were obtained by reverse genetics, as described below. All virus stocks 
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were routinely grown on L929 cells and virus titer determined by TCID50, as described (Danis 
and Lemay 1993). 
 
Sequencing of the whole VeroAV genome 
Viral genomic RNA was prepared and fragments for sequencing were generated by RT-
PCR, as previously described (Brochu-Lafontaine and Lemay, 2012), except that Vertrel was 
used in replacement of Freon to prepare reovirus virions (Mendez et al., 2000). 
 
Reovirus reverse genetics 
The plasmids separately harboring each of the cDNA corresponding to the 10 genes of 
reovirus serotype 3 Dearing, T3DK, under the transcriptional control of the T7 promoter were 
originally obtained from the laboratory of Dr. Terence Dermody (Vanderbilt University, 
Nashville, Tennessee) (Kobayashi et al. 2007). The recovery of the wild-type laboratory stock 
T3DS was initially achieved by first submitting each plasmid to site-directed mutagenesis for 
each of the gene segment differing between T3DS and T3DK (Lanoie and Lemay 2018; 
Sandekian and Lemay 2015a). 
The 4 plasmids encoding proteins that differ between the wild-type T3DS and VeroAV 
were modified to reconstitute the 4 VeroAV genes; two of them (S1 and M2) were already 
described (Sandekian and Lemay 2015b), while the other two (M1 and M3) were obtained by 
site-directed mutagenesis. 
The S1 gene of T3DS was further modified by site-directed mutagenesis to separately 
introduce each of the two amino acids substitutions in σ1. In another construct, the initiation 
codon for the small σ1s protein encoded in a second reading frame, was mutated (from ATG to 
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ACG on the plasmid) in order to prevent the synthesis of this second protein, as described by 
others (Boehme et al. 2009); this construct was referred to as knockout (KO). Sequences of all 
primers used in mutagenesis are available upon request. 
Plasmids were then used to recover infectious virus by the reverse genetics approach 
using transfection in BHK cells expressing the T7 RNA polymerase (Kobayashi et al. 2010) and 
rescued viruses were propagated as described before (Brochu-Lafontaine and Lemay 2012; 
Sandekian et al. 2015a,b). 
 
Determination of interferon induction 
ELISA assay was performed on different dilutions of the tissue culture medium to 
determine the concentration of both β-interferon and all subtypes of α-interferon (Verikine 
mouse interferon beta and alpha ELISA kit, PBL Assay Science). 
 
Determination of interferon sensitivity 
Mouse type I ß-interferon was obtained from PBL interferon source. Interferon sensitivity 
was determined on mouse L929 cells using different approaches. In a first approach, decreased 
virus titer at near-saturating (200 IU/ml) concentration on L929 cells was measured by TCID50, 
as previously used (Sandekian and Lemay 2015a; Lanoie and Lemay 2018). Secondly, 
twofold dilutions of interferon were prepared from 250 IU/ml to approximately 4 IU/ml in single 
wells of a 96 wells microplates seeded with L929 cells; cells were then infected with the different 
viruses at a MOI of 0.05, incubated for 4–5 days before being fixed and stained with methylene 
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Fig. 1. Comparison of interferon induction by the two rescued viruses. L929 cells were 
infected at a MOI of 20 TCID50 units per cell with either the rescued parental wild-type T3DS or 
the rescued VeroAV. Infected cells media were recovered at 15-hour post-infection and directly 
used in commercial ELISA assays, as described in Materials and methods. Quantitation of 
secreted β-interferon or α-interferons are presented, as indicated. Results are shown as the 
average of two independent experiments with error bars representing the standard error of the 







Fig. 2. Interferon sensitivity of T3DS harboring VeroAV genes. VeroAV genes were 
separately introduced in the T3DS background, except for the S1 gene that was introduced in 
combination with M2. Also, VeroAV S1 gene harboring either the two mutations corresponding 
to Q78P or N198K substitutions in σ1 were separately introduced in the T3DS background in 
combination with VeroAV M2 gene. Virus titers in the absence or presence of 200 IU/ml of ß-
interferon were compared, as described in the text. Fold reductions in titers due to interferon 
presence are presented on a logarithmic scale. Error bars indicate the highest value obtained in 
two or more experiments. The two viruses that are not significantly different from VeroAV, using 






Fig. 3. Sensitivity of reassortant viruses to different interferon concentrations. The same 
viruses as in Fig. 2 were examined by the interferon dilution assay, as described in Materials and 
methods. The percentage of cell destruction, as determined by optical density of methylene blue 
stain compared to mock-infected cells, is presented, as described in Materials and methods. On 
the upper panel the two parental viruses are compared with viruses harboring a single gene 
reassortment or the M2-S1 combination while the lower panel presents the two single substitution 
mutants in S1. Result are presented as the average with error bars representing standard error of 
the mean (n=5 for T3DS and VeroAV; n=2 for other viruses in the upper panel and n=3 for other 
viruses in the bottom panel). Using student’s t-test to compare results at all different interferon 
concentrations, only two viruses M2+S1-AV [T3DS] and M2-AV+S1(Q78P) [T3DS] were 






Fig. 4. Interferon sensitivity of the σ1s-null (knockout) virus. Viruses knockout (K/O) for 
the σ1s protein (in the T3DS S1 gene) in the presence or absence of the VeroAV M2 gene, as 
described in the text, were compared with the Q78P mutant virus. Virus titers in the absence or 
presence of 200 IU/ml of ß- interferon were compared, as described in the text. Fold reductions in 
titers due to interferon presence are presented on a logarithmic scale. Error bars indicate the 
highest value obtained in at least two replicate experiments. The difference between T3DS and 
the mutant was statistically significant at p <0.0001 (*) while the difference between the mutant 
and either of the two K/O viruses was significant at p <0.05 (**) using Student’s t-test; there was 
no significant difference (n.s.) between the two K/O viruses (p >0.5). 
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